Citation: | JIA S L, DU J B, SU X H. The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging[J]. CT Theory and Applications, 2024, 33(1): 35-41. DOI: 10.15953/j.ctta.2023.073. (in Chinese). |
Objectives: To evaluate the diagnostic performance of the 2018 version of liver reporting and date system (LI-RADS v2018) for hepatocellular carcinoma (HCC) on contrast-enhanced magnetic resonance imaging (MRI) in high-risk patients. Methods: The data from 69 patients with HCC confirmed by pathology from 2017 and 2022 were retrospectively analyzed. The MRI features of the HCC lesions were analyzed and categorized according to LI-RADS v2018. The efficacy of LI-RADS v2018 in the diagnosis of HCC was calculated based on pathology. The intraclass correlation coefficient (ICC) test was used for consistency analysis. Results: The ICC value of the LI-RADS categories was 0.782 (95%CI: 0.713 to 0.841) across three readers based on the Liver Imaging Reporting and Data System (LI-RADS) criteria. When using LR-5 as the criterion to predict HCCs, the sensitivity, specificity and accuracy for each reader were 83.9%, 70.4%, and 79.8%; 80.6%, 74.1%, and 78.7%; and 80.6%, 77.8%, and 79.8%, respectively. When using LR-4/5 as the criterion to predict HCCs, these measures for each reader were 93.5%, 63.0%, and 84.3%; 90.3%, 66.7%, and 83.1%; and 91.9%, 66.7%, and 84.3%, respectively. Conclusion: Based on LI-RADS v2018, the enhanced MRI demonstrated high diagnostic efficacy for HCC in high-risk patients.
[1] |
LEE J, CHANG J I, JIN Y J, et al. Recurrence of hepatoccellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection[J]. European Journal of Gastroenterology & Hepatology,2023,35(4): 431−439.
|
[2] |
PSILOPATIS I, DAMASKOS C, GARMPI A, et al. FDA-Apporoved monoclonal antibodies for unresectable hepatocellular carcinoma: What do we know so far?[J]. International Journal of Molecular Sciences, 2023, 24(3): 2685.
|
[3] |
MARRERO J A, KULIK L M, SIRLIN C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723−750. DOI: 10.1002/hep.29913.
|
[4] |
POMFRET E, WASHBURN K, WALD C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States[J]. Liver Transplant, 2010, 16(3): 262−278. DOI:10. 1002/lt.21999.
|
[5] |
American College of Radiology. CT/MRI Liver Imaging Reporting and Data System version 2014[EB/OL]. https://www.acr.org/media/ACR/Files/Clinical-Resources/LIRADS/LI-RADS-2014-Flash-Cards.pdf.
|
[6] |
American College of Radiology. CT/MRI Liver Imaging Reporting and Data System version 2017[EB/OL]. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI- LI-RADS-v2017.
|
[7] |
American College of Radiology. CT/MRI liver imaging reporting and data system version 2018[EB/OL]. https://www.acr.org/Clinical-Resources/Reporting-and-Data-System/LI-RADS/CT-MRI-LI-RADS-v2018.
|
[8] |
HANLON C A, DOWDLE L T, MOSS H, et al. Mobilization of medial and lateral frontal-striatal circuits in cocaine users and controls: An interleaved TMS/BOLD functional connectivity study[J]. Neuropsychopharmacol, 2016, 41(13): 3032−3041. DOI: 10.1038/npp.2016.114.
|
[9] |
LI X, DU L, SAHLEM G L, et al. Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex reduces resting-state insula activity and modulates functional connectivity of the orbitofrontal cortex in cigarette smokers[J]. Drug Alcohol Depen, 2017, 174: 98−105. DOI: 10.1016/j.drugalcdep.2017.02.002.
|
[10] |
SU H, LIU Y, YIN D, et al. Neuroplastic changes in resting-state functional connectivity after rTMS intervention for methamphetamine craving[J]. Neuropharmacology, 2020, 175: 108177. DOI: 10.1016/j.neuropharm.2020.108177.
|
[11] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志,2020,36(2): 277−292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
|
[12] |
JEON S, JOO I, LEE D, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging[J]. European Journal of Radiology, 2019, 29(1): 373−382. DOI: 10.1007/s00330-018-5605-x.
|
[13] |
REN A H, ZHAO P F, YANG D W, et al. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017[J]. Journal of Magnetic Resonance Imaging, 2019, 50(3): 746−755. DOI: 10.1002/jmri.26640.
|
[14] |
KANG J H, CHOI S H, BYUN J H, et al. Ancillary features in the liver imaging reporting and data system: How to improve diagnosis of hepatocellular carcinoma
|
[15] |
GAETANO A M D, CATALANO M, POMPILI M, et al. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (
|
[16] |
CERNY M, BERGERON C, BILLIARD J S, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: Performance of major and ancillary features[J]. Radiology, 2018, 288(1): 118−128. DOI: 10.1148/radiol.2018171678.
|
[17] |
CERNY M, CHERNYAK V, OLIVIE D, et al. LI-RADS version 2018 ancillary features at MRI[J]. Radiographics, 2018, 38(7): 1973−2001. DOI: 10.1148/rg.2018180052.
|
[18] |
Van der WERF Y D, SANZ-ARIGITA E J, MENNING S, et al. Modulating spontaneous brain activity using repetitive transcranial magnetic stimulation[J]. BioMed Central Neuroscience, 2010, 11(1): 145. DOI:10. 1186/1471-2202-11-145.
|
[19] |
OCKER M, MAYR C, KIESSLICH T, et al. Immunmodulatory treatment strategies of hepatocellular carcinoma: From checkpoint inhibitors now to an integrated approach in the future[J]. Cancers, 2021, 13(7): 1558.
|
[20] |
CHAUDHARI V, KHOBRAGADE K, BHANDARE M, et al. Management of fibrolamellar hepatocellular carcinoma[J]. Chinese Clincal Oncology, 2018, 7(5): 51. DOI: 10.21037/cco.2018.08.08.
|
[21] |
AN C, KIM M. Imaging features related with prognosis of hepatocellular carcinoma[J]. Abdominal Radiology (NY), 2019, 44(2): 509−516. DOI: 10.1007/s00261-018-1758-y.
|